Study completions

Study completion SURPASS-CVOT: tirzepatide against dulaglutide on major cardiovascular events

Source: A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

Study completion EMPA-KIDNEY: empagliflozin in a broad range of chronic kidney disease

Source: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Study completion FLOW: semaglutide and kidney outcomes in type 2 diabetes with chronic kidney disease

Source: A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

Study completion SELECT: semaglutide and cardiovascular outcomes in overweight or obesity

Source: Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Study completion ISCHEMIA (initial invasive or conservative strategy for stable coronary disease)

Source: International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Study completion TTM2

Source: Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest

Study completion CLEAR Outcomes (bempedoic acid in statin-intolerant people)

Source: Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo

Study completion WHO HEARTS evaluation in Bangladesh

Source: HEARTS Package Evaluation Trial in Bangladesh

Study completion SECURE

Source: Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Study completion DELIVER

Source: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

Study completion EMPEROR-Preserved

Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Study completion China Salt Substitute and Stroke Study (SSaSS)

Source: China Salt Substitute and Stroke Study

Study completion Look AHEAD: intensive lifestyle intervention in type 2 diabetes

Source: Look AHEAD: Action for Health in Diabetes

Study completion DAPA-CKD: dapagliflozin in chronic kidney disease

Source: A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease

Study completion EMPEROR-Reduced

Source: EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

Study completion FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes

Source: Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Study completion DAPA-HF

Source: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Study completion Systolic Blood Pressure Intervention Trial (SPRINT)

Source: Systolic Blood Pressure Intervention Trial (SPRINT)

Study completion Apple Heart Study

Source: Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias

Study completion DECLARE-TIMI 58: dapagliflozin and cardiovascular outcomes in type 2 diabetes

Source: Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Study completion ODYSSEY OUTCOMES (alirocumab after acute coronary syndrome)

Source: ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab

Study completion FOURIER (evolocumab in people with cardiovascular disease)

Source: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Study completion DANISH

Source: Danish ICD Study in Patients With Dilated Cardiomyopathy

Study completion LEADER: liraglutide and cardiovascular events in type 2 diabetes

Source: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results

Study completion EMPA-REG OUTCOME: empagliflozin and cardiovascular outcomes in type 2 diabetes

Source: BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Study completion CHAMPION trial

Source: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients

Study completion IMPROVE-IT (ezetimibe added to simvastatin after acute coronary syndrome)

Source: IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103)

Study completion PARADIGM-HF

Source: This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Study completion PROTECT AF

Source: WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation (PROTECT AF)

Study completion ARISTOTLE

Source: Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)

Study completion ROCKET AF

Source: An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation (ROCKET AF)

Study completion HF-ACTION

Source: Exercise Training Program to Improve Clinical Outcomes in Individuals With Congestive Heart Failure

Study completion SCD-HeFT

Source: Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

Study completion DASH-Sodium

Source: Dietary Patterns, Sodium Intake and Blood Pressure (DASH - Sodium)